TerraultN.A., AdeyD.B.The kidney transplant recipient with hepatitis C infection: pre- and posttransplantation treatment.Clin J Am Soc Nephrol2007; 2: 563–75.
2.
RostaingL., ChatelutE., PayenJ.L., IzopetJ., ThalamasC., Ton-ThatH.Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications.J Am Soc Nephrol1998; 9: 2344–8.
3.
Kidney Disease: Improving Global Outcomes (KDIGO).KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease.Kidney Int Suppl2008; (109): S1–99.
4.
GhanyM.G., StraderD.B., ThomasD.L., SeeffL.B.on behalf of the American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update.Hepatology2009; 49: 1335–74.
5.
ChanT.M., HoS.K., TangC.S., TseK.C., LamM.F., LaiK.N.Pilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infection.Nephrology (Carlton)2007; 12: 11–17.
6.
MimuraI., IshibashiY., TateishiR., KanameS., FujitaT.Pegylated interferon alpha-2a monotherapy in a peritoneal dialysis patient with chronic hepatitis C.NDT Plus2008; 1: 233–5.
7.
TaeH.J., JunD.W., ChoiJ.W., KimW.J., KimB.Y., SohnJ.H.A case of pegylated interferon alpha-2a monotherapy in a peritoneal dialysis patient with chronic hepatitis C [Korean].Korean J Gastroenterol2011; 58: 107–10.
8.
GresserI.Biologic effects of interferons.J Invest Dermatol1990; 95: 66S–71S.
9.
TrownP.W., WillsR.J., KammJ.J.The preclinical development of Roferon-A.Cancer1986; 57: 1648–56.
10.
ChouC.Y., WangI.K., LiuJ.H., LinH.H., WangS.M., HuangC.C.Comparing survival between peritoneal dialysis and hemodialysis treatment in ESRD patients with chronic hepatitis C infection.Perit Dial Int2010; 30: 86–90.
11.
KauA., VermehrenJ., SarrazinC.Treatment predictors of a sustained virologic response in hepatitis B and C.J Hepatol2008; 49: 634–51.
